Abstract
Introduction: Myxoid soft tissue tumors represent a heterogenous group of neoplasms. The study presented our experience on cytopathology of myxoid soft tissue tumors on fine needle aspiration (FNA) and aimed to apply the recently proposed WHO system for reporting soft tissue cytopathology. Material and Methods: We performed a 20-year retrospective search of our archives to identify all FNAs performed on myxoid soft tissue lesions. All cases were reviewed, and the WHO reporting system was applied. Results: 129 FNAs performed in 121 patients (62 males; 59 females) showed a prominent myxoid component, accounting for 2.4% of all soft tissue FNAs. The FNAs were performed on 111 (86.7%) primary tumors, 17 (13.2%) recurrent tumors, and one (0.8%) metastatic lesion. A spectrum of non-neoplastic and neoplastic lesions including both benign and malignant neoplasms was identified. Overall, the most common tumors identified were myxoid liposarcoma (27.1%), intramuscular myxoma (15.5%), and myxofibrosarcoma (13.1%). The sensitivity and specificity of FNA regarding the nature of the lesion (benign vs. malignant) were 98% and 100%, respectively. When the WHO reporting system was applied, the frequency of the categories was as follows: benign (7.8%), atypical (34.1%), soft tissue neoplasm of uncertain malignant potential (18.6%), suspicious for malignancy (3.1%), and malignant (36.4%). The risk of malignancy calculated in each category was as follows: benign (10%), atypical (31.8%), soft tissue neoplasm of uncertain malignant potential (50%), suspicious for malignancy (100%), and malignant (100%). Conclusion: A diverse group of non-neoplastic and neoplastic lesions can show a prominent myxoid component on FNA. The WHO reporting system for soft tissue cytopathology is easily applicable and appears to correlate well with the malignant potential of myxoid tumors.
References
1.
Wong NL, DI F. [Fine needle aspiration cytology of myxoid lesions of soft tissues: a study of 24 cases]. Zhonghua Bing Li Xue Za Zhi. 2007 Sep;36(9):619–23.
2.
Satturwar S, Wakely PE, Pantanowitz L. Approach to FNA of Myxoid Soft Tissue Tumors. Adv Anat Pathol. 2022;29(6):380–8.
3.
Layfield LJ, Dodd L, Klijanienko J. Myxoid neoplasms of bone and soft tissue: a pattern-based approach. J Am Soc Cytopathol. 2021;10:278–92.
4.
Ding S, Lu A, Chen X, Xu B, Wu N, Edoo MIA, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration: a single-center analysis. Int J Med Sci. 2020;17(17):2861–8.
5.
Cibas ES, Ali SZ. The bethesda system for reporting thyroid cytopathology. Thyroid. 2009;19(11):1159–65.
6.
Garg S, Handa U, Mohan H, Janmeja AK. Comparative analysis of various cytohistological techniques in diagnosis of lung diseases. Diagn Cytopathol. 2007 Jan;35(1):26–31.
7.
Salehi S, Maleki Z. Diagnostic challenges and problem cases in salivary gland cytology: a 20-year experience. Cancer Cytopathol. 2018 Feb 1;126(2):101–11.
8.
Domanski HA. Role of fine needle aspiration cytology in the diagnosis of soft tissue tumours. Cytopathology. 2020;31:271–9.
9.
Köster J, Ghanei I, Domanski HA. Comparative cytological and histological assessment of 828 primary soft tissue and bone lesions, and proposal for a system for reporting soft tissue cytopathology. Cytopathology. 2021 Jan 1;32(1):7–19.
10.
Willems SM, Schrage YM, Baelde JJ, Briaire-de Bruijn I, Mohseny A, Sciot R, et al. Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in composition. Histopathology. 2008 Mar;52(4):465–74.
11.
Fletcher CDM. Distinctive soft tissue tumors of the head and neck. Mod Pathol. 2002 Mar;15(3):324–30.
12.
Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone: report of 11 cases. 1948. Cancer. 1998 Jan 1;82(1):8–34.
13.
Mito JK, Mitra D, Doyle LA. Radiation-associated sarcomas: an update on clinical, histologic, and molecular features. Surg Pathol Clin. 2019;12:139–48.
14.
Lima PMd A, Oliveira MP, da Silva HJ, de Mello RJV. The role of cytology in the diagnosis of musculoskeletal neoplasms: systematic review. Acta Ortop Bras. 2012;20(1):48–52.
15.
Kilpatrick SE, Ward WG, Bos GD. The value of fine-needle aspiration biopsy in the differential diagnosis of adult myxoid sarcoma. Cancer. 2000 Jun 25;90(3):167–77.
16.
Wakely PE, Geisinger KR, Cappellari JO, Silverman JF, Frable WJ. Fine-needle aspiration cytopathology of soft tissue: chondromyxoid and myxoid lesions. Diagn Cytopathol. 1995;12(2):101–5.
17.
Klijanienko J, Caillaud JM, Lagacé R. Fine-needle aspiration in liposarcoma: cytohistologic correlative study including well-differentiated, myxoid, and pleomorphic variants. Diagn Cytopathol. 2004 May;30(5):307–12.
18.
Walaas L, Kindblom LG. Lipomatous tumors: a correlative cytologic and histologic study of 27 tumors examined by fine needle aspiration cytology. Hum Pathol. 1985 Jan;16(1):6–18.
19.
Szadowska A, Lasota J. Fine needle aspiration cytology of myxoid liposarcoma; a study of 18 tumours. Cytopathology. 1993;4(2):99–106.
20.
Wakely PE, Jin M. Myxoid liposarcoma: fine-needle aspiration cytopathology in the molecular era. A report of 24 cases. J Am Soc Cytopathol. 2016 May 1;5(3):162–9.
21.
Powers MP, Wang WL, Hernandez VS, Patel KS, Lev DC, Lazar AJ, et al. Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay. Mod Pathol. 2010 Oct;23(10):1307–15.
22.
Scapa JV, Cloutier JM, Raghavan SS, Peters-Schulze G, Varma S, Charville GW. DDIT3 immunohistochemistry is a useful tool for the diagnosis of myxoid liposarcoma. Am J Surg Pathol. 2021 Feb 1;45(2):230–9.
23.
Zulfiqar MI, Sheikh UN, Montgomery EA. Myxoid neoplasms. Surg Pathol Clin. 2011;4:843–64.
24.
Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977 Apr;39(4):1672–85.
25.
Merck C, Hagmar B. Myxofibrosarcoma: a correlative cytologic and histologic study of 13 cases examined by fine needle aspiration cytology. Acta Cytol. 1980;24(2):137–44.
26.
Olson MT, Ali SZ. Myxofibrosarcoma: cytomorphologic findings and differential diagnosis on fine needle aspiration. Acta Cytol. 2012;56(1):15–24.
27.
Kilpatrick SE, Ward WG. Myxofibrosarcoma of soft tissues: cytomorphologic analysis of a series. Diagn Cytopathol. 1999 Jan;20(1):6–9.
28.
Colin P, Lagacé R, Caillaud JM, Sastre-Garau X, Klijanienko J. Fine-needle aspiration in myxofibrosarcoma: experience of Institut Curie. Diagn Cytopathol. 2010 May;38(5):343–6.
29.
Wakely PE. Cytopathology of myxofibrosarcoma: a study of 66 cases and literature review. J Am Soc Cytopathol. 2021;10(3):300–9.
30.
Mustafa S, VandenBussche CJ, Ali SZ, Siddiqui MT, Wakely PE. Cytomorphologic findings of low-grade fibromyxoid sarcoma. J Am Soc Cytopathol. 2020 May 1;9(3):191–201.
31.
Doyle LA, Möller E, Dal Cin P, Fletcher CDM, Mertens F, Hornick JL. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Pathol. 2011 May;35(5):733–41.
32.
Mertens F, Fletcher CDM, Antonescu CR, Coindre JM, Colecchia M, Domanski HA, et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest. 2005 Mar;85(3):408–15.
33.
Matsuyama A, Hisaoka M, Shimajiri S, Hayashi T, Imamura T, Ishida T, et al. Molecular detection of FUS-CREB3L2 fusion transcripts in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens. Am J Surg Pathol. 2006 Sep;30(9):1077–84.
34.
Lau PPL, Lui PCW, Lau GTC, Yau DTW, Cheung ETY, Chan JKC. EWSR1-CREB3L1 gene fusion: a novel alternative molecular aberration of low-grade fibromyxoid sarcoma. Am J Surg Pathol. 2013 May;37(5):734–8.
35.
Sioletic S, Dal Cin P, Fletcher CDM, Hornick JL. Well-differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: analysis of 56 cases. Histopathology. 2013 Jan;62(2):287–93.
36.
Wakely PE, Wangsiricharoen S, Ali SZ. Pleomorphic liposarcoma: a clinicopathologic study of 20 FNA cases. Cancer Cytopathol. 2022 Sep;130(9):705–13.
37.
Ananthamurthy A, Nisheena R, Rao B, Correa M. Extraskeletal myxoid chondrosarcoma: diagnosis of a rare soft tissue tumor based on fine needle aspiration cytology. J Cytol. 2009 Jan;26(1):36–8.
38.
Laforga JB, Gasent JM. Fine-needle aspiration cytology of extraskeletal myxoid chondrosarcoma: a case report. Diagn Cytopathol. 2010 Apr;38(4):283–6.
39.
Wakely PE. Extraskeletal myxoid chondrosarcoma: combining cytopathology with molecular testing to achieve diagnostic accuracy. J Am Soc Cytopathol. 2021;10(3):293–9.
40.
Jakowski JD, Wakely PE. Cytopathology of extraskeletal myxoid chondrosarcoma: report of 8 cases. Cancer. 2007 Oct 25;111(5):298–305.
41.
Chiusole B, Le Cesne A, Rastrelli M, Maruzzo M, Lorenzi M, Cappellesso R, et al. Extraskeletal myxoid chondrosarcoma: clinical and molecular characteristics and outcomes of patients treated at two institutions. Front Oncol. 2020 Jun 16;10:828.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
